Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma

被引：0
作者：
Robert M Eager
C Casey Cunningham
Neil N Senzer
Joe Stephenson
Stephen P Anthony
Steven J O'Day
Gary Frenette
Anna C Pavlick
Barry Jones
Margaret Uprichard
John Nemunaitis
机构：
[1] Mary Crowley Cancer Research Centers,Clinical Research Unit
[2] Texas Oncology PA,Department of Dermatology
[3] Baylor Sammons Cancer Center,Department of Internal Medicine
[4] Gradalis,undefined
[5] Inc,undefined
[6] Cancer Centers of the Carolinas,undefined
[7] Cancer Care Northwest,undefined
[8] The Angeles Clinic and Research Institute,undefined
[9] Carolinas Medical Center,undefined
[10] New York University Clinical Cancer Center,undefined
[11] Point Therapeutics,undefined
[12] Inc,undefined
[13] The University of Hawaii,undefined
来源：
BMC Cancer | / 9卷
关键词：
Metastatic Melanoma; Evaluable Patient; Dipeptidyl Peptidase; Fibroblast Activation Protein; Index Lesion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Phase II assessment of talabostat and cisplatin in second-line stage IV melanoma
    Eager, Robert M.
    Cunningham, C. Casey
    Senzer, Neil N.
    Stephenson, Joe, Jr.
    Anthony, Stephen P.
    O'Day, Steven J.
    Frenette, Gary
    Pavlick, Anna C.
    Jones, Barry
    Uprichard, Margaret
    Nemunaitis, John
    BMC CANCER, 2009, 9
  • [2] Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan:: a phase II multicentre trial
    Neuber, K
    Reinhold, U
    Deutschmann, A
    Pföhler, C
    Mohr, P
    Pichlmeier, U
    Baumgart, J
    Hauschild, A
    MELANOMA RESEARCH, 2003, 13 (01) : 81 - 85
  • [3] Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
    Hauschild, Axel
    Agarwala, Sanjiv S.
    Trefzer, Uwe
    Hogg, David
    Robert, Caroline
    Hersey, Peter
    Eggermont, Alexander
    Grabbe, Stephan
    Gonzalez, Rene
    Gille, Jens
    Peschel, Christian
    Schadendorf, Dirk
    Garbe, Claus
    O'Day, Steven
    Daud, Adil
    White, J. Michael
    Xia, Chenghua
    Patel, Kiran
    Kirkwood, John M.
    Keilholz, Ulrich
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) : 2823 - 2830
  • [4] Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2 :: a phase II trial
    Thivat, E
    Durando, X
    D'Incan, M
    Cure, H
    Mouret-Reynier, MA
    Madelmont, JC
    Souteyrand, P
    Chollet, P
    ANTI-CANCER DRUGS, 2005, 16 (09) : 1003 - 1007
  • [5] Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma
    Geoerger, Birgit
    Bergeron, Christophe
    Gore, Lia
    Sender, Leonard
    Dunkel, Ira J.
    Herzog, Cynthia
    Brochez, Lieve
    Cruz, Ofelia
    Nysom, Karsten
    Berghorn, Elmer
    Simsek, Burcin
    Shen, Jun
    Pappo, Alberto
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 358 - 363
  • [6] Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma
    Rao, RD
    Holtan, SG
    Ingle, JN
    Croghan, GA
    Kottschade, LA
    Creagan, ET
    Kaur, JS
    Pitot, HC
    Markovic, SN
    CANCER, 2006, 106 (02) : 375 - 382
  • [7] Phase II Study of Nab-Paclitaxel and Bevacizumab as First-line Therapy for Patients with Unresectable Stage III and IV Melanoma
    Spitler, Lynn E.
    Boasberg, Peter
    O' Day, Steven
    Hamid, Omid
    Cruickshank, Scott
    Mesko, Shane
    Weber, Robert W.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2015, 38 (01): : 61 - 67
  • [8] Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group
    Gogas, H
    Bafaloukos, D
    Aravantinos, G
    Fountzilas, G
    Tsoutsos, D
    Panagiotou, P
    Frangia, K
    Kalofonos, HP
    Briasoulis, E
    Castana, O
    Polyzos, A
    Pectasides, D
    Ioannovich, J
    CANCER INVESTIGATION, 2004, 22 (06) : 832 - 839
  • [9] Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma
    Eroglu, Zeynep
    Kong, Kevin M.
    Jakowatz, James G.
    Samlowski, Wolfram
    Fruehauf, John P.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (04) : 1081 - 1087
  • [10] A Phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma
    Richard Kefford
    Jane McNeil Beith
    Guy Arthur Van Hazel
    Michael Millward
    James Marshall Trotter
    David Keith Wyld
    Rada Kusic
    Revati Shreeniwas
    Adele Morganti
    Andrea Ballmer
    Eleonor Segal
    Oliver Nayler
    Martine Clozel
    Investigational New Drugs, 2007, 25 : 247 - 252
12345